California is currently home to 5616 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
Recruiting
This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Gastrointestinal Cancer, Peritoneal Carcinomatosis
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Recruiting
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Artiva Clinical Trial Site, Foster City, California
Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/06/2025
Locations: UCI Center for Clinical Research, Irvine, California
Conditions: Myotonic Dystrophy 1
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Recruiting
This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to severe OUD in a 2:1 ratio to one of two medication conditions: (1) XR-BUP (128mg target), administered every 4 weeks or (2) SL-BUP (16mg-24 mg/day target).Participants will receive study medication trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Southern Humboldt Community Healthcare District - Jerold Phelps Community Hospital, Garberville, California
Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
LGMD R1 Natural History Study
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: University of California, Irvine, Orange, California
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Recruiting
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
06/06/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Congenital Myotonic Dystrophy, CDM
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of California Irvine, Irvine, California
Conditions: Generalized Myasthenia Gravis
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recruiting
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/06/2025
Locations: Travere Investigational Site, Los Angeles, California
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, Alport Syndrome, IgA Vasculitis
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2025
Locations: University of California, Davis Health, Sacramento, California
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: City of Hope, Duarte, California
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Recruiting
This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/05/2025
Locations: University of California Davis, Sacramento, California
Conditions: Metastatic Lobular Breast Carcinoma
Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support
Recruiting
The proposed study is a quality improvement initiative designed to rigorously evaluate new variations of UCLA Health's proton pump inhibitor (PPI) order panels, building on internal quality improvement efforts to optimize prescribing workflows within the Electronic Health Record (EHR). PPIs are notoriously overprescribed, and the study team has identified that the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/05/2025
Locations: UCLA Health System, Los Angeles, California
Conditions: Prescribing Patterns, Physician, Physician's Practice Patterns, Drug Utilization Review